The Centers for Medicare & Medicaid Services announced a 2.48% increase in 2027 Medicare Advantage capitation rates, exceeding initial expectations of 0.09%. The boost amounts to over $13 billion in additional payments and reflects a 4.98% increase when accounting for risk score trends. CMS retained the 2024 risk adjustment model, providing greater rate predictability for insurers. Major healthcare stocks surged on the positive announcement.

Johnson Fistel is investigating Elevance Health, Inc. following the company's disclosure that the Centers for Medicare & Medicaid Services intends to impose intermediate sanctions, including suspension of enrollment into certain Medicare Advantage-Prescription Drug plans effective March 31, 2026. The law firm is examining whether Elevance and its executives complied with federal securities laws. Investors who suffered losses are encouraged to contact the firm.

Elevance Health (ELV) stock declined 7.23% on Monday after the Centers for Medicare & Medicaid Services (CMS) froze the company's Medicare Advantage enrollment effective March 31, 2026. The freeze stems from alleged noncompliance with risk adjustment data submission requirements, including the company's repeated use of USB drives instead of CMS-mandated electronic systems since November 2018. This regulatory action compounds earlier concerns from the company's weak 2026 guidance and CMS's proposed minimal payment increases for Medicare Advantage plans.

Humana shares plummeted 13.49% in premarket trading following the Trump administration's proposal for nearly flat Medicare Advantage payment rates for 2027, with only a 0.09% net average payment increase versus Wall Street expectations of 4-6%. The broader health insurance sector also suffered significant losses, with CVS Health, UnitedHealth Group, and Elevance Health all declining sharply.

The Centers for Medicare & Medicaid Services (CMS) proposed a 2027 Medicare Advantage payment increase of only 0.09%, significantly below Wall Street's expectations of 4-6%. This modest growth announcement triggered sharp declines in major health insurer stocks, with UnitedHealth, Humana, and CVS Health leading the losses. The CMS emphasized program sustainability and payment accuracy through updated risk adjustment models.

UnitedHealth Group CEO Stephen Hemsley testified before House panels that rising hospital prices, consolidation, and prescription drug costs—not insurers—are the primary drivers of U.S. health care spending. He pledged to voluntarily eliminate and rebate profits on ACA exchange coverage this year and urged policy reforms including site-neutral payments and patent reform. UnitedHealth also announced a pilot program to accelerate Medicare Advantage payments for rural hospitals.

As US stocks start 2026 with positive momentum and the S&P 500 near record highs above 6,900 points, three previously underperforming stocks show signs of recovery. Flowco Holdings is forming a rounding pattern with potential upside to $26, Elevance Health is testing key resistance at $360 with a path to $450, and Matador Resources shows strong fundamentals with a 50% fair value gap and potential recovery above $53.

Hyperion Capital Advisors acquired 540,000 shares of Vertex (VERX) worth $13.39 million in Q3, making it the fund's third-largest holding. Despite a 63% stock decline over the past year, the investment signals confidence in Vertex's underlying business fundamentals, including 12.7% revenue growth, 30% cloud revenue growth, and strong cash generation with a $150 million share buyback authorization.

The White House is preparing to introduce a healthcare framework to extend Affordable Care Act subsidies, proposing a two-year extension with updated eligibility limits and measures to control premium increases affecting approximately 22 million Americans.

With market volatility increasing, the article highlights three dividend-paying stocks that reported strong Q3 earnings: Travelers Companies, Elevance Health, and Church & Dwight. These stocks offer potential stability and consistent income amid uncertain market conditions.

Molina Healthcare reported disappointing annual guidance, causing stocks of healthcare insurance providers Centene and Oscar Health to decline. The company expects higher medical cost trends across segments, particularly in the Marketplace, impacting investor confidence.

Elevance Health reported Q3 2025 operating revenue of $50.1 billion, a 12% increase from 2024, with diluted EPS of $5.32. The company maintained full-year guidance despite challenges in Medicaid membership and increased medical costs.